Robert Bazemore (Epizyme)
Robert Bazemore inks one last deal for Epizyme — adding China to Tazverik's global blueprint — before heading out from CEO office
Among the early pioneers of China biotech, Hutchmed (then Chi-Med) stood out for a reason: It largely stayed out of in-licensing drugs from Western drugmakers, choosing instead to hunker down on developing its own compounds — notching big partners in AstraZeneca and Eli Lilly for savolitinib and fruquintinib, both on the market now, along the way.
As its peers begin heralding in-house discovery to complement the externally-sourced parts of the pipeline, though, Hutchmed is once again going in the opposite direction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
